Workflow
华之杰(603400):股权激励计划点评:激励计划高举高打,新业务有望贡献高增长:华之杰(603400):
市公司 防疫 公司古 | 公 | | --- | | 司 | | 研 | | 究 | | / | | 公 | | 司 | | 市场数据: | 2026年02月26日 | | --- | --- | | 收盘价(元) | 73.18 | | 一年内最高/最低(元) | 97.00/46.15 | | 市净率 | 5.8 | | 股息率%(分红/股价) | 1.23 | | 流通 A 股市值 (百万元) | 1.464 | | 上证指数/深证成指 | 4,146.63/14,503.79 | | 基础数据: | 2025年09月30日 | | --- | --- | | 每股净资产 (元) | 12.59 | | 资产负债率% | 31.07 | | 总股本/流通 A 股 (百万) | 100/20 | | 流通 B 股/H 股 (百万) | -/- | -年内股价与大需对 | 信势: 相关研究 证券分析师 刘正 A0230518100001 liuzheng@swsresearch.com 刘嘉玲 A0230522120003 liujl@swsresearch.com 联系人 程恺雯 A02305240800 ...
惠而浦(600983):拟认购惠而浦集团普通股,进一步深化合作
GOLDEN SUN SECURITIES· 2026-02-26 13:03
Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The subscription of shares by Whirlpool China is expected to strengthen the global collaboration and influence of the company, enhancing cooperation with the group [2] - The current dividend yield for WHR is 4.95%, indicating a favorable financial return [2] - Future growth is anticipated due to the company's ability to secure orders from Whirlpool Group, increased OEM releases in Japan and Southeast Asia, cost reduction and efficiency improvements after the acquisition of Galanz, and changes in competitive dynamics [2] Financial Projections - The company is projected to achieve net profits of 505 million, 616 million, and 743 million yuan for the years 2025, 2026, and 2027, respectively, representing year-on-year growth rates of 150.5%, 21.8%, and 20.7% [2] - Revenue is expected to grow from 4,455 million yuan in 2025 to 6,454 million yuan in 2027, with corresponding growth rates of 22.1%, 21.1%, and 19.7% [3] - The latest diluted EPS is projected to increase from 0.66 yuan in 2025 to 0.97 yuan in 2027 [3] Financial Metrics - The company’s total revenue for 2023 is reported at 4,004 million yuan, with a projected decline of 6.1% year-on-year [3] - The net profit for 2023 is reported at 81 million yuan, with a significant year-on-year increase of 190.4% [3] - The return on equity (ROE) is expected to rise from 3.2% in 2023 to 29.9% in 2027 [3]
安孚科技(603031):以南孚电池筑基,撬动硬科技第二曲线
Guoxin Securities· 2026-02-26 12:37
Investment Rating - The investment rating for the company is "Outperform the Market" [1] Core Insights - The company, Anfu Technology, has transformed from a retail business to a leader in the domestic small battery industry by acquiring a controlling stake in Nanfu Battery and divesting its original retail operations [3][15] - Nanfu Battery is recognized for its high profit margins, strong return on equity (ROE), and robust cash flow, maintaining a market share of over 80% in the domestic alkaline battery market [6][47] - The company is actively investing in high-tech sectors, including AI and semiconductor manufacturing, to build a second growth curve alongside its core battery business [3][5] Summary by Sections 1. Anfu Technology: Domestic Small Battery Industry Leader - Anfu Technology was established in 1984 and listed on the A-share market in 2016, initially focusing on retail [15] - In 2022, the company acquired 51% of Yajing Technology, gaining control of Nanfu Battery and successfully transitioning to the consumer battery sector [15][12] 2. Controlling Nanfu Battery: A Stable "Cash Cow" Business - Nanfu Battery has been the market leader in alkaline manganese batteries for 32 consecutive years, with a retail market share of 85.9% in alkaline 5 and 7 batteries for 2024 [6][47] - Revenue for Nanfu Battery grew from 2.18 billion to 4.64 billion (CAGR +10%) from 2016 to 2024, with net profit increasing from 500 million to 920 million (CAGR +8%) [6][53] - The company plans to acquire the remaining shares of Yajing Technology and minority stakes in Nanfu Battery to enhance profitability [6] 3. Strategic Investment in Yilaimi: Potential for "Electric + Optical" Dual Layout - Yilaimi is positioned to develop next-generation optical chips, with a production capacity supporting 200,000 to 500,000 chips annually [6] - The strategic investment in Yilaimi is part of the company's broader strategy to integrate into the semiconductor industry and explore new growth avenues [6] 4. Profit Forecast and Valuation - Revenue projections for 2025-2027 are 4.82 billion, 5.31 billion, and 5.83 billion, with year-on-year growth rates of +4.0%, +10.1%, and +9.8% respectively [6] - The estimated net profit attributable to the parent company for the same period is 235 million, 421 million, and 594 million, reflecting significant growth [6] - The stock's reasonable value range is estimated between 57.6 and 69.1 yuan, corresponding to a market capitalization of 14.85 billion to 17.81 billion [6]
拟认购惠而浦集团普通股,进一步深化合作
GOLDEN SUN SECURITIES· 2026-02-26 12:24
Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The proposed subscription of $30 million in common stock by Whirlpool China aims to strengthen global collaboration with the Whirlpool Group, enhancing its influence and deepening cooperation. The current dividend yield for WHR is 4.95%, indicating good financial returns [2] - The company is expected to benefit from increased orders from the Whirlpool Group, growth in OEM releases in Japan and Southeast Asia, cost reduction and efficiency improvements following the acquisition by Galanz, and changes in competitive dynamics within the industry. Future growth is anticipated [2] Financial Projections - Revenue is projected to grow from 4,004 million yuan in 2023 to 6,454 million yuan in 2027, with year-on-year growth rates of -6.1% in 2023, 22.1% in 2025, 21.1% in 2026, and 19.7% in 2027 [3] - Net profit attributable to the parent company is expected to increase from 81 million yuan in 2023 to 743 million yuan in 2027, with significant growth rates of 190.4% in 2024, 150.5% in 2025, 21.8% in 2026, and 20.7% in 2027 [3] - The latest diluted EPS is forecasted to rise from 0.11 yuan in 2023 to 0.97 yuan in 2027 [3] - The return on equity (ROE) is projected to improve from 3.2% in 2023 to 29.9% in 2027 [3] Valuation Metrics - The price-to-earnings (P/E) ratio is expected to decrease from 113.7 in 2023 to 12.4 in 2027, indicating a more attractive valuation over time [3] - The price-to-book (P/B) ratio is projected to remain relatively stable, ranging from 3.6 in 2023 to 3.7 in 2027 [3]
裕同科技:布局欧洲&收购华研完善AI产业链布局,迈向1+N+T成长股空间广阔-20260226
SINOLINK SECURITIES· 2026-02-26 12:24
Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [4]. Core Insights - The company has made strategic acquisitions, including a 60% stake in the Hungarian packaging company Gelbert for €6.54 million (approximately 53.48 million RMB), which positions it to establish a foothold in the European market [1]. - The acquisition of Gelbert is valued at 6.4 times the target company's 2024 EBITDA, suggesting a low valuation and potential for growth through local production and service capabilities [2]. - The company also plans to acquire a 51% stake in Dongguan Huayan Technology for 449 million RMB, with performance-based valuation adjustments tied to future profit targets [2][3]. - The overall valuation for Huayan Technology is set at 880 million RMB, reflecting an 8x multiple on the average target net profit for 2026-2028, indicating strong support from major shareholders [3]. - The company's strategy focuses on expanding beyond packaging into non-packaging sectors, enhancing supply chain integration, and targeting new consumer markets, which is expected to drive future revenue growth [3]. Financial Projections - The company is projected to achieve earnings per share (EPS) of 1.78, 1.93, and 2.30 RMB for the years 2025 to 2027, respectively, with corresponding price-to-earnings (P/E) ratios of 18, 16, and 14 [4]. - Revenue forecasts indicate a decline of 6.96% in 2023, followed by growth rates of 12.71% in 2024 and 4.29% in 2025, with further increases expected in subsequent years [9]. - The net profit attributable to the parent company is expected to decrease slightly in 2023 but is projected to grow significantly by 16.21% in 2025 and 18.94% in 2027 [9].
华之杰(603400):股权激励计划点评:激励计划高举高打,新业务有望贡献高增长
上 市 公 司 公 司 研 究 / 公 司 点 评 证 券 研 究 报 告 | 公 | | --- | | 司 | | 研 | | 究 | | / | | 公 | | 司 | | 市场数据: | 2026 年 02 月 26 日 | | --- | --- | | 收盘价(元) | 73.18 | | 一年内最高/最低(元) | 97.00/46.15 | | 市净率 | 5.8 | | 股息率%(分红/股价) | 1.23 | | 流通 A 股市值(百万元) | 1,464 | | 上证指数/深证成指 | 4,146.63/14,503.79 | 注:"股息率"以最近一年已公布分红计算 | 基础数据: | 2025 年 09 月 30 日 | | --- | --- | | 每股净资产(元) | 12.59 | | 资产负债率% | 31.07 | | 总股本/流通 A 股(百万) | 100/20 | | 流通 B 股/H 股(百万) | -/- | 一年内股价与大盘对比走势: 证券分析师 刘正 A0230518100001 liuzheng@swsresearch.com 刘嘉玲 A0230522120 ...
虹软科技(688088):利润持续释放,智驾业务维持高增
HTSC· 2026-02-26 12:05
证券研究报告 虹软科技 (688088 CH) 利润持续释放,智驾业务维持高增 | 华泰研究 | | | 动态点评 | 投资评级(维持): | 买入 | | --- | --- | --- | --- | --- | --- | | 2026 年 | 2 月 | 26 日│中国内地 | 计算机应用 | 目标价(人民币): | 71.27 | 虹软科技发布 2025 年业绩预告:预计营收 9.23 亿,yoy+13.22%;归母净 利 2.58 亿,yoy+45.86%;扣非净利 2.13 亿,yoy+36.85%。利润快速增长 主要得益于智驾营收高增长驱动该业务持续减亏。公司整体营收及归母净利 略低于我们预期(营收 10.21 亿,归母净利 2.84 亿),预计主要受部分手 机 IP 算法及智驾业务确收延期影响,智能终端及智驾业务收入增速低于我 们预期。展望未来,公司智能驾驶业务营收有望维持高增长,高利润率的智 能终端业务营收维持稳健增长,公司整体利润有望持续释放,维持买入评级。 25Q4 单季:收入同比+23%左右,归母净利同比+32%左右 虹软 25Q1-Q3 营收同比增速分别为 13.77%、2.08% ...
兆易创新(603986):避开AI风暴眼,兆易创新在“利基市场”默默赚翻
市值风云· 2026-02-26 11:20
导语:行业周期上行与技术布局落地的双重轨迹。 风云君注意到,近期存储设计龙头兆易创新(603986.SH)也交出了一份亮眼的 业绩预告,预计全年营业收入 92.03 亿元,同比增长 25%;归母净利润 16.1 亿 元,同比增长 46%。 高速增长的背后,则是行业周期上行与技术布局落地的双重轨迹。 一、AI 风暴眼外,一片被巨头遗忘的市场 兆易创新以"感存算控连"为技术整合方向,其业务布局分为三大板块:存储、 控制、感知。 虽说各板块在客户与应用场景上相互交叉,但目前存储板块依旧是绝对核心。 2025 年上半年,兆易创新存储芯片实现收入 28.45 亿元,贡献出总营收的三分 之二。 作者:市值风云 App:萧瑟 避开 AI 风暴眼,兆易创新在"利基市场"默默赚翻 2 月 9 日,根据 TrendForce 最新数据显示,得益于 AI 浪潮的推升,存储器产 业受供给吃紧与价格飙升影响,预计 2026 年产值规模将大幅扩张至 5516 亿美 元,创下历史新高。 答案倒也未必。 长期以来,三星、SK 海力士、美光科技三大厂都在陆续退出利基 DRAM 市场; 兆易创新作为填补这部分空白的角色,2024 年利基 DRA ...
裕同科技(002831):布局欧洲&收购华研完善AI产业链布局,迈向1+N+T成长股空间广阔
SINOLINK SECURITIES· 2026-02-26 11:19
Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The company has made strategic acquisitions to enhance its market presence in Europe and diversify its operations beyond packaging [2][3] - The acquisition of Gelbert, a Hungarian packaging company, allows the company to leverage Gelbert's established customer network and market reputation in Central and Eastern Europe, improving local production and delivery capabilities [2] - The acquisition of a 51% stake in Dongguan Huayan Technology for 449 million yuan is expected to directly enhance the company's overall performance and integrate into the core supply chain of its clients [3] - The company is transitioning from a growth-oriented model to a more integrated service capability, aiming to expand into new consumer sectors such as AI and trendy products [3] Summary by Sections Event Summary - On February 25, the company announced the acquisition of 60% of Gelbert for 6.54 million euros (approximately 53.48 million yuan), marking its entry into the European core market [1] Operational Analysis - The acquisition price corresponds to a low valuation of 6.4 times the target company's 2024 EBITDA, indicating a favorable entry point [2] - The company aims to enhance its local service capabilities and order acquisition through this strategic move [2] - The acquisition of Huayan Technology is valued at 880 million yuan, representing 8 times the average target net profit for 2026-2028, reflecting strong support from major shareholders [3] Financial Forecasts and Valuation - The company is projected to have EPS of 1.78, 1.93, and 2.30 yuan for 2025-2027, with current PE ratios of 18, 16, and 14 times respectively [4] - Revenue is expected to grow from 15,223 million yuan in 2023 to 22,468 million yuan by 2027, with a compound annual growth rate of approximately 12.47% [9]
亿帆医药(002019):创新药主业稳健发展,泛酸钙价格处周期底部
Guotou Securities· 2026-02-26 11:15
2026 年 02 月 26 日 亿帆医药(002019.SZ) 创新药主业稳健发展,泛酸钙价格处周 期底部 创新管线持续丰富且核心产品稳定放量,公司主业稳健发展: 公司坚定执行"创新、国际化"中长期发展规划,持续强化公司创新 管线布局,推动主业稳健发展。创新生物药亿立舒已取得阶段性成果, 在中国、美国、欧盟、巴西、阿曼和挪威等多个国家获准上市销售, 2025 年国内外累计发货量超 50 万支,同比增长超 80%。此外,公司 从尚德药缘引入拟用于治疗小细胞肺癌脑转移的 1 类创新药 ACT001, ACT001 是与放化疗及免疫治疗有协同作用的新一代免疫调节剂,通 过抑制癌症病灶组织微环境中相关细胞的 NF-κB 和 STAT3 信号通路, 降低肿瘤细胞 DNA 修复能力,以及对放化疗和免疫治疗的双重协同 作用,达到局部肿瘤控制和生存期延长的效果。 泛酸钙价格处于历史底部区间,后续价格改善值得期待 公司核心原料药产品为维生素 B5(泛酸钙),需求端得益于动物营养 和食品添加剂方面需求的稳定增长,泛酸钙全球市场规模稳步增长。 供给端格局较为集中,供给厂家主要包括亿帆医药、新发药业、帝斯 曼、巴斯夫、兄弟科技等。 ...